Key facts
- Notable investors include Viking Global Investors, Cure EB, DEBRA Research, EB Research Partnership, Epidermolysis Bullosa Medical Research Foundation.
- Status: Privately Held (backing).
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Nova Anchora
Create free account
No card required
Funding rounds
1 roundsApr 2025Early Stage VC—▮
About Nova Anchora
Operator of a biotechnology company intended to develop advanced protein therapy. The company's corrective protein therapy cures a severe, rare skin disease, enabling patients to get cured quickly.
- Industry
- Biotechnology
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2021
- Employees
- 2
- Website
- novaanchora.com/
- Ownership
- Privately Held (backing)
PA Mark — not yet priced
Nova Anchora doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Nova Anchora shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Nova Anchora in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.